Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Nuvation Bio (NUVB) Shares Outstanding (Diluted Average) (2022 - 2026)

Nuvation Bio has reported Shares Outstanding (Diluted Average) over the past 5 years, most recently at $377521.0 for Q1 2026.

  • Quarterly Shares Outstanding (Diluted Average) rose 11.49% to $377521.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $377521.0 through Mar 2026, up 11.49% year-over-year, with the annual reading at $341541.0 for FY2025, 27.07% up from the prior year.
  • Shares Outstanding (Diluted Average) was $377521.0 for Q1 2026 at Nuvation Bio, up from $341541.0 in the prior quarter.
  • Over five years, Shares Outstanding (Diluted Average) peaked at $377521.0 in Q1 2026 and troughed at $216721.0 in Q4 2022.
  • The 5-year median for Shares Outstanding (Diluted Average) is $245311.5 (2024), against an average of $272161.9.
  • Year-over-year, Shares Outstanding (Diluted Average) grew 0.14% in 2024 and then soared 54.58% in 2025.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $216721.0 in 2022, then grew by 1.0% to $218880.0 in 2023, then grew by 22.79% to $268772.0 in 2024, then increased by 27.07% to $341541.0 in 2025, then rose by 10.53% to $377521.0 in 2026.
  • Per Business Quant, the three most recent readings for NUVB's Shares Outstanding (Diluted Average) are $377521.0 (Q1 2026), $341541.0 (Q4 2025), and $342393.0 (Q3 2025).